Labcorp launches assay to measure LAG-3 expression in skin cancer

1024px Melanoma e1652951424740

Life sciences company Labcorp has launched a new test to measure expression levels of the lymphocyte activation gene 3 (LAG-3) by immunohistochemistry (IHC) in tumor tissues from people with prostate cancer. the skin.

The LAG-3-IHC test, which is believed to have shown demonstrable clinical benefit in patients with melanoma, is available for use in clinical studies and patient treatment.

Prasanth Reddy, senior vice president and head of oncology at Labcorp, said, “Our goal is to provide diagnostic solutions that can help guide the clinical application of new cancer treatments, thereby improving the lives of people with cancer.

READ MORE:  Farewell to the iPod, the device that ushered in too much choice | Rebecca Nicholson

“The LAG-3 IHC test provides physicians with actionable information to evaluate the best treatment options, including newly approved treatments and clinical trials, for their patients.”

The test was developed by Labcorp Drug Development for use in a clinical trial studying dual checkpoint inhibitors, including LAG-3 immunotherapy.

Assessment of LAG-3 status in tumors, as well as the correlation between expression level and response to LAG-3 immunotherapy, can be provided by the assay.

READ MORE:  Musk says Twitter may charge slight fee for commercial, government users

Additionally, the test is being used in other ongoing clinical studies analyzing the clinical response to LAG-3-targeted cancer therapies.

Skin cancer is the most common cancer in the United States. Although melanoma is one of the rarest types of cancer, it carries a higher risk of spreading to other parts of the body.

Changes in the appearance of an existing mole are among the first signs of melanoma. The only approach to diagnosing melanoma is tissue biopsy, which can be performed at most healthcare facilities.

READ MORE:  Global Employee Assistance Program Market Procurement Intelligence Report to Have an Incremental Spend of USD 4.34 Billion| SpendEdge

Earlier this week, the Food and Drug Administration (FDA) approved Labcorp’s Seasonal Respiratory Virus DTC RT-PCR Test for non-prescription use to detect influenza, respiratory syncytial virus (RSV), and SARS- CoV-2.

This approval will allow people with symptoms of Covid-19 to purchase the test without needing a prescription.

Related companies

main 70

Picosun Logo Agile ALD RGB

lead 2

Source link

Leave a Comment